Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia.

IF 2.1 4区 医学 Q3 ONCOLOGY
Ajda Drofenik, Ales Blinc, Mojca Bozic Mijovski, Tadej Pajic, Matjaz Vrtovec, Matjaz Sever
{"title":"Relation of <i>JAK2</i> V617F allele burden and coronary calcium score in patients with essential thrombocythemia.","authors":"Ajda Drofenik, Ales Blinc, Mojca Bozic Mijovski, Tadej Pajic, Matjaz Vrtovec, Matjaz Sever","doi":"10.2478/raon-2024-0036","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>JAK2</i> V617F (<i>JAK2</i>) mutation is associated with clonal hemopoiesis in myeloproliferative neoplasms as well as with faster progression of cardiovascular diseases. Little is known about the relationship between allele burden and the degree of atherosclerotic alteration of coronary vasculature. We previously reported that carotid artery stiffness progressed faster in patients with <i>JAK2</i> positive essential thromocythemia (ET) patients. After a four-year follow-up we investigated whether mutation burden of a <i>JAK2</i> allele correlates with a higher coronary calcium score.</p><p><strong>Patients and methods: </strong>Thirty-six patients with <i>JAK2</i> positive ET and 38 healthy matched control subjects were examined twice within four years. At each visit clinical baseline characteristics and laboratory testing were performed, <i>JAK2</i> mutation burden was determined, and coronary calcium was measured.</p><p><strong>Results: </strong><i>JAK2</i> allele burden decreased in 19 patients, did not change in 5 patients, and increased in 4 patients. The coronary calcium Agatston score increased slightly in both groups. Overall, there was no correlation between <i>JAK2</i> allele burden and calcium burden of coronary arteries. However, in patients with the <i>JAK2</i> mutation burden increase, the coronary calcium score increased as well.</p><p><strong>Conclusions: </strong>The average <i>JAK2</i> allele burden decreased in our patients with high-risk ET during the four-year period. However, in the small subgroup whose <i>JAK2</i> mutation burden increased the Agatston coronary calcium score increased as well. This finding, which should be interpreted with caution and validated in a larger group, is in line with emerging evidence that <i>JAK2</i> mutation accelerates atherosclerosis and can be regarded as a non-classical risk factor for cardiovascular disease.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/raon-2024-0036","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: JAK2 V617F (JAK2) mutation is associated with clonal hemopoiesis in myeloproliferative neoplasms as well as with faster progression of cardiovascular diseases. Little is known about the relationship between allele burden and the degree of atherosclerotic alteration of coronary vasculature. We previously reported that carotid artery stiffness progressed faster in patients with JAK2 positive essential thromocythemia (ET) patients. After a four-year follow-up we investigated whether mutation burden of a JAK2 allele correlates with a higher coronary calcium score.

Patients and methods: Thirty-six patients with JAK2 positive ET and 38 healthy matched control subjects were examined twice within four years. At each visit clinical baseline characteristics and laboratory testing were performed, JAK2 mutation burden was determined, and coronary calcium was measured.

Results: JAK2 allele burden decreased in 19 patients, did not change in 5 patients, and increased in 4 patients. The coronary calcium Agatston score increased slightly in both groups. Overall, there was no correlation between JAK2 allele burden and calcium burden of coronary arteries. However, in patients with the JAK2 mutation burden increase, the coronary calcium score increased as well.

Conclusions: The average JAK2 allele burden decreased in our patients with high-risk ET during the four-year period. However, in the small subgroup whose JAK2 mutation burden increased the Agatston coronary calcium score increased as well. This finding, which should be interpreted with caution and validated in a larger group, is in line with emerging evidence that JAK2 mutation accelerates atherosclerosis and can be regarded as a non-classical risk factor for cardiovascular disease.

JAK2 V617F等位基因负担与原发性血小板增多症患者冠状动脉钙化评分的关系
背景:JAK2 V617F(JAK2)突变与骨髓增殖性肿瘤的克隆性造血以及心血管疾病的快速进展有关。人们对等位基因负荷与冠状动脉血管粥样硬化改变程度之间的关系知之甚少。我们以前曾报道过,JAK2 阳性的重型血栓性血小板增多症(ET)患者的颈动脉僵化进展较快。经过四年的随访,我们研究了JAK2等位基因的突变负荷是否与较高的冠状动脉钙化评分相关:我们在四年内对 36 名 JAK2 阳性 ET 患者和 38 名健康的匹配对照受试者进行了两次检查。每次就诊时都进行了临床基线特征和实验室检测,确定了 JAK2 基因突变负荷,并测量了冠状动脉钙:结果:19 名患者的 JAK2 等位基因负荷减少,5 名患者没有变化,4 名患者增加。两组患者的冠状动脉钙化 Agatston 评分均略有上升。总体而言,JAK2等位基因负荷与冠状动脉钙负荷之间没有相关性。然而,在JAK2突变负荷增加的患者中,冠状动脉钙化评分也增加了:结论:在四年的时间里,高危ET患者的平均JAK2等位基因负荷有所下降。结论:在我们的高危 ET 患者中,JAK2 等位基因的平均负荷在四年期间有所下降,但在 JAK2 突变负荷增加的一小部分亚组中,Agatston 冠状动脉钙化评分也有所增加。这一发现符合新出现的证据,即JAK2突变会加速动脉粥样硬化,可被视为心血管疾病的非典型风险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Radiology and Oncology
Radiology and Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
4.40
自引率
0.00%
发文量
42
审稿时长
>12 weeks
期刊介绍: Radiology and Oncology is a multidisciplinary journal devoted to the publishing original and high quality scientific papers and review articles, pertinent to diagnostic and interventional radiology, computerized tomography, magnetic resonance, ultrasound, nuclear medicine, radiotherapy, clinical and experimental oncology, radiobiology, medical physics and radiation protection. Therefore, the scope of the journal is to cover beside radiology the diagnostic and therapeutic aspects in oncology, which distinguishes it from other journals in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信